Hospital
State University of Iowa
State University of Iowa was paid $90.10M by Medicaid between Jan 2018 and Dec 2024, across 455 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 61% of everything it billed.
33Billing provider infoSTATE UNIVERSITY OF IOWA
IOWA CITY, IA 52242
IOWA CITY, IA 52242
33aNPI1376544320assigned 08/02/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$90.10M
24GClaims1,455,666
24DCodes billed455
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Iowa
Rank by total paid#1 of 29
Median peer was paid$6.37M
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 221,417 | $10.57M | |
| 2019 | 223,071 | $12.31M | |
| 2020 | 183,175 | $11.45M | |
| 2021 | 229,923 | $15.58M | |
| 2022 | 227,630 | $14.96M | |
| 2023 | 216,675 | $14.21M | |
| 2024incomplete | 153,775 | $11.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 61% | 598,678 | 534,843 | $54.87M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 3,520 | 3,075 | $4.78M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.9% | 19,609 | 18,643 | $2.60M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.7% | 4,334 | 4,128 | $1.58M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.5% | 7,268 | 6,801 | $1.34M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.3% | 25,691 | 24,744 | $1.19M |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 1.3% | 613 | 455 | $1.17M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 2,761 | 2,506 | $1.02M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,590 | 4,189 | $794K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16,337 | 14,916 | $788K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 2,036 | 1,856 | $712K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 2,926 | 2,651 | $648K |
443 more codes
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 527 | $630K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 872 | $623K |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 1,159 | $567K |
| 92587 | <1% | 2,966 | $566K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 666 | $504K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 438 | $503K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 10,350 | $457K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,255 | $424K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,815 | $420K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,940 | $398K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 4,213 | $394K |
| 94060 | <1% | 2,264 | $380K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 974 | $377K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,447 | $363K |
| 76770 | <1% | 4,449 | $358K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 4,323 | $346K |
| 92523 | <1% | 2,680 | $338K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 3,177 | $329K |
| 59025 | Fetal non-stress test | <1% | 2,556 | $329K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 4,155 | $315K |
| 82947 | <1% | 9,900 | $304K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,073 | $302K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 4,210 | $293K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,863 | $268K |
| 20611 | <1% | 1,401 | $266K | |
| 96112 | <1% | 2,407 | $262K | |
| 90870 | <1% | 2,413 | $261K | |
| 95782 | <1% | 347 | $251K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,091 | $250K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,089 | $237K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 970 | $223K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,741 | $214K |
| 90686 | <1% | 12,328 | $209K | |
| 29450 | <1% | 1,480 | $203K | |
| 16020 | <1% | 1,368 | $196K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,044 | $192K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,940 | $189K |
| 95813 | <1% | 803 | $180K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,804 | $175K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,912 | $171K |
| 31231 | <1% | 1,435 | $165K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 42 | $163K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,754 | $157K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,763 | $156K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,968 | $155K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 1,093 | $147K |
| 31575 | <1% | 1,069 | $132K | |
| 90670 | <1% | 1,931 | $123K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,975 | $120K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 22,008 | $119K |
| 91065 | <1% | 1,132 | $116K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,696 | $115K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,391 | $110K |
| 77386 | <1% | 312 | $108K | |
| 74183 | <1% | 455 | $104K | |
| 95800 | <1% | 1,044 | $104K | |
| 96127 | <1% | 6,364 | $97K | |
| G0378 | Hospital observation service, per hour | <1% | 3,672 | $96K |
| 92610 | <1% | 1,441 | $93K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,016 | $93K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 981 | $91K |
| 96101 | <1% | 952 | $88K | |
| 77080 | <1% | 1,315 | $77K | |
| 92557 | <1% | 2,544 | $77K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 132,888 | $72K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 9,253 | $70K |
| G0008 | Administration of influenza virus vaccine | <1% | 2,259 | $69K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,353 | $68K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 85 | $67K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,110 | $66K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 128 | $66K |
| 81229 | <1% | 58 | $59K | |
| 90837 | Psychotherapy session, about an hour | <1% | 567 | $57K |
| 76830 | Ultrasound, transvaginal | <1% | 670 | $54K |
| 80061 | Lipid panel | <1% | 4,540 | $51K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 578 | $50K |
| 94010 | <1% | 5,061 | $43K | |
| 95811 | <1% | 89 | $43K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14,151 | $42K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 378 | $39K |
| 96111 | <1% | 335 | $39K | |
| 11721 | <1% | 1,854 | $39K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 357 | $38K |
| 97165 | <1% | 792 | $34K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 77 | $34K |
| 20610 | <1% | 208 | $34K | |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 490 | $32K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 569 | $29K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 54,718 | $29K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 75 | $29K |
| 72082 | <1% | 2,622 | $28K | |
| 93296 | <1% | 1,289 | $27K | |
| 71250 | <1% | 390 | $27K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 185 | $27K |
| 97161 | <1% | 510 | $27K | |
| 96130 | <1% | 749 | $26K | |
| 93226 | <1% | 365 | $23K | |
| 97803 | <1% | 1,961 | $22K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 59 | $22K |
| 76642 | <1% | 507 | $22K | |
| 90697 | <1% | 524 | $21K | |
| 80053 | Comprehensive metabolic panel | <1% | 14,423 | $21K |
| 91320 | <1% | 213 | $20K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 650 | $19K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 580 | $19K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 521 | $19K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 37 | $18K |
| 76536 | <1% | 575 | $18K | |
| 0001A | <1% | 478 | $18K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 112 | $18K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,804 | $17K |
| 96415 | <1% | 319 | $17K | |
| 92604 | <1% | 175 | $17K | |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | <1% | 551 | $16K |
| 0002A | <1% | 458 | $15K | |
| 97166 | <1% | 264 | $15K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 84 | $14K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 556 | $14K |
| 90480 | <1% | 385 | $13K | |
| 90723 | <1% | 479 | $13K | |
| 95812 | <1% | 75 | $13K | |
| 84439 | <1% | 5,979 | $12K | |
| 93271 | <1% | 163 | $12K | |
| 97167 | <1% | 211 | $11K | |
| 76825 | <1% | 27 | $11K | |
| 77072 | <1% | 1,118 | $11K | |
| 82728 | <1% | 4,449 | $11K | |
| 86900 | <1% | 795 | $10K | |
| 76801 | <1% | 110 | $10K | |
| 93975 | <1% | 75 | $10K | |
| 74230 | <1% | 122 | $9K | |
| 82565 | <1% | 17,038 | $9K | |
| 95970 | <1% | 458 | $9K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 304 | $9K |
| 81479 | Unlisted molecular pathology procedure | <1% | 203 | $9K |
| 73030 | <1% | 1,828 | $9K | |
| 87536 | <1% | 574 | $9K | |
| 96409 | <1% | 48 | $9K | |
| 92522 | <1% | 131 | $9K | |
| 77066 | Tomosynthesis, mammo | <1% | 99 | $9K |
| 76881 | <1% | 91 | $8K | |
| 92611 | <1% | 126 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 694 | $8K |
| 92134 | <1% | 7,087 | $8K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 271 | $8K |
| 97162 | <1% | 154 | $8K | |
| 64642 | <1% | 16 | $8K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 786 | $8K |
| 92083 | <1% | 1,522 | $8K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 96 | $7K |
| 90688 | <1% | 643 | $7K | |
| 84520 | <1% | 13,291 | $7K | |
| 0072A | <1% | 250 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 319 | $7K |
| 97802 | <1% | 371 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 649 | $7K |
| 75561 | <1% | 12 | $7K | |
| 76882 | <1% | 129 | $6K | |
| 64483 | <1% | 12 | $6K | |
| 73630 | <1% | 1,194 | $6K | |
| 96136 | <1% | 698 | $6K | |
| 77336 | <1% | 70 | $6K | |
| 96137 | <1% | 776 | $6K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 162 | $6K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 125 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,010 | $6K |
| 17110 | <1% | 134 | $6K | |
| 87081 | <1% | 860 | $5K | |
| 86780 | <1% | 371 | $5K | |
| 94726 | <1% | 332 | $5K | |
| 84295 | <1% | 8,892 | $5K | |
| 90651 | <1% | 87 | $5K | |
| 84132 | <1% | 8,272 | $5K | |
| 83880 | <1% | 611 | $5K | |
| 82374 | <1% | 8,602 | $5K | |
| 80051 | <1% | 1,430 | $5K | |
| 84403 | <1% | 1,002 | $5K | |
| 82435 | <1% | 8,550 | $5K | |
| 90656 | <1% | 1,413 | $5K | |
| 90677 | <1% | 321 | $5K | |
| 85027 | <1% | 8,707 | $4K | |
| 82670 | <1% | 825 | $4K | |
| 0071A | <1% | 189 | $4K | |
| 84460 | <1% | 7,324 | $4K | |
| 73564 | <1% | 572 | $4K | |
| 82310 | <1% | 7,846 | $4K | |
| 69210 | <1% | 328 | $4K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,336 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 7,218 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 170 | $4K |
| 84466 | <1% | 3,014 | $4K | |
| 0124A | <1% | 131 | $4K | |
| 72141 | <1% | 30 | $4K | |
| 82977 | <1% | 3,003 | $4K | |
| 84450 | <1% | 6,472 | $4K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 44 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,127 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,034 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,094 | $3K |
| 29075 | <1% | 15 | $3K | |
| 73610 | <1% | 651 | $3K | |
| 82570 | <1% | 2,623 | $3K | |
| 83520 | <1% | 777 | $3K | |
| 73502 | <1% | 540 | $3K | |
| 96138 | <1% | 69 | $3K | |
| 82040 | <1% | 5,502 | $3K | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 497 | $3K |
| 74018 | <1% | 389 | $3K | |
| 81001 | <1% | 7,266 | $3K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 182 | $3K |
| 82248 | <1% | 2,021 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13 | $3K |
| 82465 | <1% | 420 | $3K | |
| 83735 | <1% | 1,607 | $2K | |
| 93225 | <1% | 91 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 278 | $2K |
| 96116 | <1% | 16 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 415 | $2K |
| 85610 | <1% | 2,692 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,938 | $2K |
| 83718 | <1% | 420 | $2K | |
| 72170 | <1% | 266 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 97 | $2K |
| 95983 | <1% | 85 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 729 | $2K |
| 88142 | <1% | 419 | $2K | |
| 83540 | <1% | 2,980 | $2K | |
| 92582 | <1% | 26 | $2K | |
| 83970 | <1% | 612 | $2K | |
| 93297 | <1% | 95 | $2K | |
| 76885 | <1% | 54 | $2K | |
| 84478 | <1% | 420 | $2K | |
| 90619 | <1% | 55 | $2K | |
| 82105 | <1% | 1,299 | $2K | |
| 72100 | <1% | 193 | $2K | |
| 73110 | <1% | 417 | $2K | |
| 0054A | <1% | 56 | $2K | |
| 84075 | <1% | 3,823 | $2K | |
| 80197 | <1% | 601 | $2K | |
| 92567 | <1% | 4,474 | $2K | |
| 84100 | <1% | 2,119 | $2K | |
| 82247 | <1% | 3,562 | $2K | |
| 92250 | <1% | 39 | $2K | |
| 87480 | <1% | 95 | $1K | |
| 86803 | <1% | 332 | $1K | |
| 0004A | <1% | 65 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 69 | $1K |
| 97799 | <1% | 83 | $1K | |
| 86480 | <1% | 36 | $1K | |
| 85045 | <1% | 3,681 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 614 | $1K |
| 82607 | <1% | 838 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 100 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 322 | $1K |
| 84156 | <1% | 1,700 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,407 | $1K |
| 36591 | <1% | 501 | $1K | |
| 87510 | <1% | 95 | $1K | |
| 73590 | <1% | 526 | $1K | |
| 73521 | <1% | 112 | $1K | |
| 84155 | <1% | 3,203 | $1K | |
| 73562 | <1% | 382 | $1K | |
| 84703 | <1% | 202 | $1K | |
| 90685 | <1% | 308 | $1K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 15 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 16 | $1K |
| 80069 | <1% | 621 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,520 | $1K |
| 99152 | <1% | 405 | $993.21 | |
| 96131 | <1% | 35 | $973.57 | |
| 73560 | <1% | 176 | $967.60 | |
| 92607 | <1% | 12 | $893.70 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 180 | $879.98 |
| 82043 | <1% | 985 | $876.06 | |
| 82784 | <1% | 469 | $744.01 | |
| 90734 | <1% | 16 | $743.60 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 23 | $743.25 |
| 81243 | <1% | 14 | $708.79 | |
| 0154A | <1% | 28 | $682.21 | |
| 86140 | <1% | 2,108 | $669.19 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 654 | $647.16 |
| 0082A | <1% | 26 | $640.00 | |
| 92593 | <1% | 53 | $624.82 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,179 | $562.96 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 720 | $562.91 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 135 | $544.29 |
| 70250 | <1% | 57 | $541.34 | |
| 83655 | <1% | 161 | $524.40 | |
| 86361 | <1% | 139 | $522.18 | |
| 0081A | <1% | 19 | $480.00 | |
| 36592 | <1% | 19 | $457.20 | |
| 85651 | <1% | 1,368 | $443.22 | |
| 92595 | <1% | 38 | $435.31 | |
| 87077 | <1% | 271 | $431.41 | |
| 90680 | <1% | 703 | $420.19 | |
| 73130 | <1% | 105 | $419.83 | |
| 90671 | <1% | 17 | $419.72 | |
| 87799 | <1% | 20 | $408.63 | |
| 93325 | <1% | 3,489 | $404.14 | |
| 0052A | <1% | 13 | $400.96 | |
| 82379 | <1% | 101 | $394.83 | |
| 86850 | <1% | 1,978 | $385.86 | |
| 86706 | <1% | 210 | $382.84 | |
| 0112A | <1% | 18 | $360.00 | |
| 80076 | <1% | 434 | $349.77 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 16 | $345.53 |
| 87340 | <1% | 248 | $331.42 | |
| 81003 | <1% | 2,635 | $326.77 | |
| 86704 | <1% | 123 | $321.15 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 12 | $317.56 |
| J3490 | Unclassified drugs | <1% | 864 | $305.97 |
| 92592 | <1% | 38 | $295.86 | |
| 91200 | <1% | 12 | $284.71 | |
| 86160 | <1% | 98 | $275.70 | |
| 94618 | <1% | 18 | $275.06 | |
| 83020 | <1% | 150 | $251.31 | |
| 95976 | <1% | 14 | $246.33 | |
| 92555 | <1% | 488 | $238.72 | |
| 86255 | <1% | 137 | $227.96 | |
| 92133 | <1% | 378 | $224.75 | |
| 82274 | <1% | 12 | $223.92 | |
| 93320 | <1% | 1,983 | $211.75 | |
| 0111A | <1% | 12 | $200.00 | |
| 83615 | <1% | 569 | $195.06 | |
| 87186 | <1% | 50 | $192.88 | |
| 84702 | <1% | 36 | $187.64 | |
| 83516 | <1% | 113 | $186.65 | |
| 73070 | <1% | 72 | $180.55 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,058 | $176.80 |
| 87497 | <1% | 19 | $163.61 | |
| 82610 | <1% | 307 | $160.29 | |
| 93922 | <1% | 14 | $144.51 | |
| 87102 | <1% | 285 | $141.17 | |
| 92579 | <1% | 13 | $139.92 | |
| 87653 | <1% | 34 | $136.04 | |
| 83690 | <1% | 250 | $135.23 | |
| 76514 | <1% | 172 | $133.42 | |
| 81050 | <1% | 357 | $119.45 | |
| 87070 | <1% | 391 | $119.13 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 21 | $118.83 |
| 86038 | <1% | 127 | $115.18 | |
| 90648 | <1% | 1,080 | $112.60 | |
| 83605 | <1% | 279 | $101.81 | |
| 87522 | Neg quan hep c or qual rna | <1% | 17 | $100.48 |
| 76820 | <1% | 198 | $99.23 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 540 | $90.33 |
| 86364 | <1% | 31 | $88.26 | |
| 72040 | <1% | 13 | $82.32 | |
| 82785 | <1% | 280 | $82.17 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 52 | $80.86 |
| 62322 | <1% | 126 | $78.99 | |
| 86235 | <1% | 13 | $77.56 | |
| 82103 | <1% | 132 | $70.29 | |
| 82533 | <1% | 28 | $68.48 | |
| 51798 | <1% | 37 | $64.70 | |
| 85018 | <1% | 127 | $64.45 | |
| 73552 | <1% | 30 | $59.39 | |
| 92025 | <1% | 13 | $56.58 | |
| 84484 | <1% | 287 | $48.36 | |
| 82390 | <1% | 74 | $45.94 | |
| 86334 | <1% | 78 | $45.69 | |
| 94729 | <1% | 2,472 | $44.02 | |
| C1769 | Guide wire | <1% | 829 | $43.85 |
| 84153 | <1% | 14 | $43.14 | |
| 87210 | <1% | 92 | $33.18 | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 17 | $32.71 |
| 86003 | <1% | 141 | $29.86 | |
| 82140 | <1% | 60 | $28.24 | |
| 86762 | <1% | 33 | $27.88 | |
| 83883 | <1% | 80 | $27.83 | |
| 96158 | <1% | 129 | $26.51 | |
| 85014 | <1% | 69 | $25.20 | |
| 86787 | <1% | 18 | $25.08 | |
| 84165 | <1% | 78 | $21.96 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 27 | $20.96 |
| 86301 | <1% | 421 | $20.17 | |
| 82378 | <1% | 618 | $18.37 | |
| 81025 | <1% | 28 | $16.36 | |
| 86708 | <1% | 34 | $15.09 | |
| 82397 | <1% | 14 | $13.68 | |
| 85652 | <1% | 44 | $12.90 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $12.44 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 19 | $11.48 |
| 73140 | <1% | 13 | $11.07 | |
| 90715 | <1% | 270 | $8.76 | |
| L8613 | Ossicula implant | <1% | 478 | $7.95 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 9,965 | $7.55 |
| 82010 | <1% | 16 | $7.30 | |
| 86800 | <1% | 12 | $5.15 | |
| 85730 | <1% | 50 | $3.61 | |
| G0176 | Activity therapy, such as music, dance, art or play therapies not for recreation, related to the care and treatment of patient's disabling mental health problems, per session (45 minutes or more) | <1% | 156 | $3.08 |
| 86901 | <1% | 795 | $2.99 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 90 | $2.35 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 46 | $2.21 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 464 | $0.15 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 16 | $0.09 |
| 91307 | <1% | 58 | $0.02 | |
| 86580 | 0% | 15 | $0.00 | |
| 83930 | 0% | 1,945 | $0.00 | |
| 88300 | 0% | 109 | $0.00 | |
| 95885 | 0% | 129 | $0.00 | |
| 90474 | 0% | 129 | $0.00 | |
| 95012 | 0% | 34 | $0.00 | |
| 94250 | 0% | 75 | $0.00 | |
| 36416 | 0% | 510 | $0.00 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 225 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 33 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 13 | $0.00 |
| 82962 | 0% | 15 | $0.00 | |
| 96161 | 0% | 28 | $0.00 | |
| 96139 | 0% | 93 | $0.00 | |
| 94762 | 0% | 138 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 63 | $0.00 |
| 95886 | 0% | 51 | $0.00 | |
| 92499 | 0% | 39 | $0.00 | |
| 91305 | 0% | 42 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 28 | $0.00 |
| 84134 | 0% | 13 | $0.00 | |
| J1270 | Injection, doxercalciferol, 1 mcg | 0% | 337 | $0.00 |
| 83002 | 0% | 15 | $0.00 | |
| 87205 | 0% | 15 | $0.00 | |
| 91300 | 0% | 34 | $0.00 | |
| 96113 | 0% | 604 | $0.00 | |
| 85046 | 0% | 377 | $0.00 | |
| 0115U | 0% | 82 | $0.00 | |
| 96159 | 0% | 53 | $0.00 | |
| 94799 | 0% | 74 | $0.00 | |
| 95874 | 0% | 93 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 82 | $0.00 |
| 87641 | 0% | 13 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 30 | $0.00 |
| 84305 | 0% | 18 | $0.00 | |
| 90633 | 0% | 221 | $0.00 | |
| 76827 | 0% | 27 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 12 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 88 | $0.00 |
| C1729 | Catheter, drainage | 0% | 12 | $0.00 |
| 81002 | 0% | 31 | $0.00 | |
| 90785 | 0% | 42 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 19 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 18 | $0.00 |
| 84481 | 0% | 13 | $0.00 | |
| 64643 | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCKELVEY, JOE (SR DIRECTOR OF GOVERNMENT REIMB)
| Provider | Location | Paid |
|---|---|---|
| State University of Iowa | Iowa City, IA | $189K |
| State University of Iowa | Iowa City, IA | $129K |
| State University of Iowa | Coralville, IA | $20K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.